Cypherpunk Technologies (CYPH)
Builds a Zcash treasury and privacy technologies while retaining an oncology subsidiary.
Something off on this page? Send us feedback.
Builds a Zcash-centered digital-asset treasury while pursuing privacy technologies. Through its wholly owned Leap Therapeutics subsidiary, it also advances the oncology programs sirexatamab and FL-501; reported results depend on ZEC fair value and clinical, regulatory, and development outcomes.
Built around a Zcash treasury, the company accumulates ZEC and pursues investments, acquisitions, and internal development in privacy technologies.
A wholly owned Leap Therapeutics subsidiary retains the oncology pipeline, developing sirexatamab and FL-501. Sirexatamab is a DKK1-inhibiting monoclonal antibody, while FL-501 is a preclinical program for cachexia-related indications.
The Nasdaq issuer adopted the Cypherpunk Technologies name and CYPH ticker in November 2025 after operating as Leap Therapeutics. Its reported results depend materially on the fair value of the ZEC treasury, as well as clinical, regulatory, and development outcomes for the subsidiary's programs.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 1, 2026 | Cantor Fitzgerald | Initiate | Overweight |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.6M · Total debt $38.0K · Total assets $143.0M · Shareholders' equity $139.3M
- Revenue
- $0
- Operating income
- −$4.7M
- Net income
- $39.4M
No dividends on record.
| Insiders17 holders · as of Aug 27, 2026 | 2.63% | 2.84M shares | |
| Strategic holders1 holder · as of Feb 10, 2022 | 0.29% | 315.2K shares | |
| Otherremainder | 97.08% | 104.61M shares |
107.76M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Augustine LawlorInsiderofficer: Chief Operating Officer | 0.65% | 698,245 | Form 4filed Apr 1, 2025 ↗ |
Kevin ZhangInsiderofficer: Head of Mining | 0.31% | 330,904 | Form 4filed Aug 24, 2026 ↗ |
Lilly Eli & Co1Strategic10 percent owner | 0.29% | 315,161 | 13G/Afiled Feb 10, 2022 ↗ |
James H. CavanaughInsiderdirector | 0.16% | 168,963 | Form 4filed Mar 17, 2026 ↗ |
William LiInsiderdirector | 0.16% | 168,750 | Form 4filed Mar 17, 2026 ↗ |
| See all 25 → | |||
- Lilly Eli & Co's transaction reports restate only vehicles that traded; the 2022 ownership statement (315.2K) is used instead.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Thomas John Dietz | director | −20,000 | $1.72 |
| Mar 26, 2026 | Christopher Mirabelli | director | −60,000 | $0.7105 |
| Nov 17, 2025 | Douglas E. Onsi | director, officer: CEO,CFO,Pres.,GC,Treas.&Sec. | −676,319 | $3.14 |
| Nov 17, 2025 | James H. Cavanaugh | director | −261,840 | $3.14 |
| Nov 17, 2025 | Christopher Mirabelli | director | −676,319 | $3.14 |
- Reliance Global Group
ZEC-focused digital-asset treasury strategy
- Amgen
Approved biologic therapies for biomarker-defined mCRC
- Eli Lilly
Second-line mCRC therapy paired with FOLFIRI
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cypherpunk Technologies | $1.73 | +2.99% | $178.9M | 2.7 | 20.9 | — | — |
| Reliance Global Group | $2.73 | 0.00% | $1.5M | — | — | 0.1 | −31.6% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Median | 33.2 | 23.6 | 6.3 | +9.7% |